SMAP-2 (DT-1154) is an orally active protein phosphatase 2A (PP2A) activator, with anti-cancer activity In Vitro SMAP-2 reduces cell viability of pancreatic ductal adenocarcinoma (PDA) cell lines in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SMAP-2 significantly reduces abdominal aortic aneurysms (AAA) incidence and aortic dilation in pro-AAA apolipoprotein E- (ApoE-/-) mice. SMAP-2 (15 mg/kg; i.g.; daily; 6 days a week; for approximately 14 days) has anti-tumor activity in pancreatic cancer mice model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NSG mice, with PANC89 cells xenograftDosage: 15 mg/kg Administration: Oral gavage, daily, 6 days a week, for approximately 14 days Result: Decreased tumor growth and tumor weight. Form:Solid IC50& Target:PP2A
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
SMAP-2
CAS number：1809068-70-9 molecular formula：C27H27F3N2O4S
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | - | ||
| CAS number | 1809068-70-9 | molecular formula | C27H27F3N2O4S |
| molecular weight | 532.57 g/mol | Exact mass | ≥99% |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
